Cutaneous Manifestations in COVID-19 “Long Haulers”: Is This A Part of the Multisystem Inflammatory Syndrome?

Cameron Y. S. Lee^{1, 2,}

¹Private Practice, Oral, Maxillofacial and Reconstructive Surgery, Aiea, Hawaii, 96701

²Professor of Surgery, Temple University, Kornberg School of Dentistry, Philadelphia, PA, 19140

Cite this paper:
Cameron Y. S. Lee. Cutaneous Manifestations in COVID-19 “Long Haulers”: Is This A Part of the Multisystem Inflammatory Syndrome?. American Journal of Infectious Diseases and Microbiology. 2021; 9(2):48-50. doi: 10.12691/ajidm-9-2-3

Abstract

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a multisystem inflammatory syndrome that affects many different organs of the body. Extrapulmonary cutaneous manifestations are now being reported in greater frequency as occurring before or after onset of clinical symptoms. To the authors knowledge, there are few, if any published study that has documented the persistent cutaneous manifestations in patients who have recovered from COVID-19. In this report, we describe some of the cutaneous manifestations in patients known as COVID-19 “long haulers”.

Keywords:
COVID-19 long haulers persistent symptoms Cutaneous manifestations

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Rubin R. As their number grow, Covid-19. “Long Haulers” stump experts. JAMA. 2020; 324(14): 1381-1383.
[2]	Alwan NA. Surveillance is underestimating the burden of the Covid-19 pandemic. Lancet. 2020; 396 (10252):e24.
[3]	Tenforde M, Kim S, Lindsell C, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network- United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020, ePub. 24 July 2020.
[4]	Ladds E, Rushforth A, Wieringa S, et al. Persistent symptoms after Covid-19: qualitative study of 114 “long Covid” patients and draft quality principles for services. BMC Health Services Research. 2020; 20: 1144.
[5]	Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute Covid-19. JAMA. 2020; 324(6): 603-605.
[6]	Greenhalgh, T, Knight M, Burton M, et al. Management of post-acute covid-19 in primary care. BMJ. 2020; 370m3026.
[7]	Arnold DT, Hamilton FW, Milne A, et al. Patient outcomes after hospitalization with COVID-19 and implications for follow-up; results from a prospective UK cohort. medRxiv. 2020.
[8]	Goertz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post COVID-19 syndrome? ERJ Open Res. 2020; Oct 26; 6(4): 00542-2020.
[9]	Freeman EE, McMahon DE, Lipoff JB, et al. The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries. J Am Acad Dermatol. 83: 1118-1129. 2020.
[10]	Dhont S, Derom E, Van Braeckel E, et al. The pathophysiology of ‘happy’ hypoxemia in Covid-19. Respir Res. 21, 198 (2020).
[11]	Galvan Casas C, Catala A, Carretero Hernandez G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020.
[12]	Marzano AV, Cassano N, Genovese G, et al. Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue. Br J Dermatol. 2020; 183: 431-442.
[13]	Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020.
[14]	De Giorgi V, Recalcati S, Jia Z, et al. Cutaneous manifestations related to coronavirus disease 2019 (COVID-19): a prospective study from China and Italy. J Am Acad Dermatol. 83: 674-675. 2020.
[15]	Lee CYS. Cutaneous rash: A clinical manifestation prior to respiratory symptoms of Covid-19 infection. J Fam Med Dis Prev. 7: 137. 2021.
[16]	Daneshgaran G, Dubin DP, Gould DJ. Cutaneous manifestations of COVID-19: An evidenced based review. Am J Clin Dermatol. 2020.
[17]	Fernandez-Nieto D, Ortega-Quijano D, Jimenez-Cauhe J, et al. Clinical and histological characterization of vesicular COVID-19 rashes: a prospective study in a tertiary care hospital. Clin Exp Dermatol. 2020.
[18]	Tan SW, Tam YC, Oh CC. Skin manifestations of COVID-19: A worldwide review. JAAD Int. 2021. 2: 119-133.
[19]	Sanchez A, Sohier P, Benghane S, et al. Digitate papulosquamous eruption associated with severe acute respiratory syndrome Coronavirus-2 infection. JAMA Dermatol. April 30, 2020.
[20]	Gianotti R, Veraldi S, Recalcati S, et al. Cutaneous clinico-pathological findings in three COVID-19-positive patients observed in the metropolitan area of Milan, Italy. Acta Derm Venereol. 2020. [published online ahead of print, 2020 Apr 21].
[21]	Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020. [S1931-5244(20)30070- 0.
[22]	Vaduganathan M, Vardeny O, Michel T, et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020; 382: 1653-1659.
[23]	Kroumpouzos G. Cutaneous manifestations of COVID-19: An unusual presentation with edematous plaques and pruritic, erythematous papules, and comment on the role of bradykinin storm and its therapeutic implications. Dermatol Ther. 2021, e14753.
[24]	Estebanez A, Perez-Santiago L, Silva E, et al. Cutaneous manifestations in COVID-19: new contribution. J Eur Acad Dermatol Venereol. 2020; 34: e250-e251.
[25]	Liang J, He Y, Ji W. Bradykinin-evoked scratching responses in complete Freund’s adjuvant-inflamed skin through activation of B1 receptor (Maywood). 2012; 37: 318-326.
[26]	Ghahestani SM, Mahmoudi J, Hajebrahimi S, et al. Bradykinin as a probable aspect in SARS-CoV-2 scenarios: is bradykinin sneaking out of our sight? Iran J Allergy Asthma Immunol. 2020; 19(S1): 13-17.
[27]	Kaushik A, Parsad, D, Kumaran MS. Urticaria in the times of COVID-19. Dermatol Ther. 2020; e13817.
[28]	Matar S, Oules B, Sohier P, et al. Cutaneous manifestations in SARS-CoV-2 infections (COVID-19): a French experience and a systematic review of the literature. J Eur Acad Dermatol Venereol. 2020. Jun: jdv. 16775.
[29]	Hamming I, Timens W, Bulthius MLC, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004; 203: 631-637.